EVAX Overview

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Wall Street analysts forecast EVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVAX is12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Evaxion A/S revenue for the last quarter amounts to 7.49M USD, increased 148.33

Evaxion A/S. EPS for the last quarter amounts to 0.01 USD, decreased -105.56

Evaxion A/S (EVAX) has 46 emplpoyees as of March 03 2026.

Today EVAX has the market capitalization of 26.44M USD.